Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Response to Cohen et al.
- Ripu D. Jindal, MD12 and
- Matcheri S. Keshavan, MD12
- 1University of Pittsburgh, Pittsburgh, Pennsylvania
- 2Wayne State University School of Medicine, Detroit, Michigan
- Address correspondence to Ripu D. Jindal, MD, University of Pittsburgh, 3811 O’Hara St., Pittsburgh, PA 15213. E-mail: jindalr{at}upmc.edu
We commend Cohen et al. (1) on their report on hyperglycemia and diabetes in patients with schizophrenia and schizoaffective disorders. To our knowledge, this is the first large study of oral glucose tolerance tests in this population.
Cohen et al. found that the prevalence rate of diabetes was significantly higher in patients with schizophrenia and schizoaffective disorders than in the general population. They did not detect a differential effect of antipsychotic monotherapy in diabetogenic effects, and they consequently proposed a modification of the consensus statement on antipsychotic drugs, obesity, and diabetes, i.e., measurement of fasting glucose in all patients with schizophrenia irrespective of the prescribed antipsychotic drug. We …
